GO:0043691 reverse cholesterol transport: HDL-Mediated Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0043691 reverse cholesterol transport is the directed movement of peripheral cell cholesterol towards the liver for catabolism, as defined in QuickGO.
• HDL particles are the principal vehicles that accept cholesterol from macrophages and peripheral tissues and deliver it to the liver for excretion.
• The pathway begins with cholesterol efflux from cells, mediated by transporters such as ABCA1 and ABCG1, and ends with hepatic uptake and biliary or fecal elimination.
• Reverse cholesterol transport is a major protective mechanism against atherosclerosis, and its failure contributes to cardiovascular disease.
• The process is regulated by miRNAs and can be modulated by exercise and natural compounds, making it a target for therapeutic intervention.
• CRISPR-based knockout, knock-in, and overexpression models are essential tools for dissecting the causal roles of genes in reverse cholesterol transport.
Description
Reverse cholesterol transport (GO:0043691) is a biological process defined as the directed movement of peripheral cell cholesterol, cholest-5-en-3-beta-ol, towards the liver for catabolism. This pathway is central to lipid homeostasis and is widely studied because it represents the primary route by which excess cholesterol is removed from the body. The process is mediated by high-density lipoprotein (HDL) particles, which act as acceptors of cholesterol from peripheral cells, including macrophages within atherosclerotic plaques. Understanding reverse cholesterol transport is therefore critical for researchers investigating atherosclerosis, cardiovascular disease, and metabolic disorders. The pathway involves a coordinated series of steps: cholesterol efflux from cells, esterification and transport within HDL, and final uptake by the liver for biliary excretion or conversion to bile acids. Each step is regulated by specific transporters, enzymes, and apolipoproteins, and dysregulation at any point can impair cholesterol clearance and promote disease. Recent studies have also highlighted the role of active cholesterol and miRNAs in modulating this process, opening new avenues for therapeutic targeting. This article provides a comprehensive overview of the ontology, mechanisms, key genes, and research methods for studying reverse cholesterol transport, with a focus on CRISPR-based approaches for functional validation.
reverse cholesterol transport At A Glance
| GO ID | GO:0043691 |
|---|---|
| GO term | reverse cholesterol transport |
| Ontology | biological_process |
| Synonym | none |
| Major function | Transport of peripheral cholesterol to the liver for catabolism |
| Definition source | QuickGO |
| Related pathway | HDL-mediated cholesterol efflux and hepatic uptake |
| Key transporters | ABCA1, ABCG1, SR-BI |
| Physiological outcome | Cholesterol elimination and atherosclerosis protection |
What Is GO:0043691?
According to the Gene Ontology, reverse cholesterol transport (GO:0043691) is the directed movement of peripheral cell cholesterol, cholest-5-en-3-beta-ol, towards the liver for catabolism. In other words, it is the process by which cholesterol that has accumulated in cells outside the liver is transported back to the liver, where it can be broken down or excreted. This definition emphasizes both the directionality of movement (from periphery to liver) and the ultimate fate of cholesterol (catabolism).
Why Is reverse cholesterol transport Important in Cell Biology?
Reverse cholesterol transport is critically important because it is the primary mechanism by which the body eliminates excess cholesterol, and its impairment is a major risk factor for atherosclerosis and cardiovascular disease. The pathway also plays a role in macrophage foam cell formation and plaque stability, making it a key target for therapeutic interventions aimed at reducing cardiovascular risk. Furthermore, understanding reverse cholesterol transport has implications for metabolic disorders such as diabetes and non-alcoholic fatty liver disease, where cholesterol homeostasis is often disrupted.
• Protects against atherosclerosis by removing cholesterol from arterial macrophages.
• Maintains whole-body cholesterol homeostasis and prevents cholesterol accumulation in peripheral tissues.
• Is a major determinant of HDL function and cardiovascular risk.
• Dysregulation is linked to inflammation and plaque progression.
• Can be modulated by lifestyle factors such as exercise.
• Is regulated by microRNAs and natural compounds, offering therapeutic opportunities.
• Serves as a biomarker for cardiovascular disease risk assessment.
• Provides targets for drug development, including CETP inhibitors and LXR agonists.
• Involves active cholesterol, a newly recognized regulatory mechanism.
• Is essential for biliary cholesterol excretion and bile acid synthesis.
What Happens During reverse cholesterol transport?
Cholesterol Efflux from Peripheral Cells
In simple terms: Cholesterol leaves cells in peripheral tissues, such as macrophages in blood vessel walls, and enters HDL particles.
The first step of reverse cholesterol transport is the efflux of cholesterol from peripheral cells to lipid-poor apolipoprotein A-I (apoA-I) or mature HDL particles. This process is mediated by ATP-binding cassette transporters, particularly ABCA1 and ABCG1, as well as scavenger receptor BI (SR-BI). ABCA1 facilitates the transfer of cholesterol and phospholipids to lipid-poor apoA-I, forming nascent HDL, while ABCG1 promotes efflux to mature HDL. The efficiency of this step is a major determinant of overall reverse cholesterol transport capacity.
HDL Maturation and Cholesterol Esterification
In simple terms: The HDL particle grows and matures as it picks up more cholesterol, which is converted to a storage form.
After efflux, free cholesterol on the surface of HDL is esterified by lecithin-cholesterol acyltransferase (LCAT) to cholesteryl ester, which moves into the core of the HDL particle, allowing further cholesterol uptake. This maturation process converts nascent, discoidal HDL into spherical, mature HDL. Cholesteryl ester transfer protein (CETP) can transfer cholesteryl esters from HDL to apoB-containing lipoproteins, such as VLDL and LDL, in exchange for triglycerides, providing an alternative route for cholesterol delivery to the liver.
Hepatic Uptake of Cholesterol
In simple terms: The liver takes up cholesterol from HDL particles through specific receptors.
Mature HDL delivers cholesteryl esters to the liver via selective uptake mediated by scavenger receptor class B type I (SR-BI). SR-BI binds HDL and facilitates the transfer of cholesteryl esters into hepatocytes without internalizing the entire particle. Alternatively, apoB-containing lipoproteins carrying cholesteryl esters from CETP can be taken up by the liver via the LDL receptor. This step ensures that cholesterol is delivered to the liver for final elimination.
Biliary Excretion and Catabolism
In simple terms: The liver disposes of cholesterol by secreting it into bile or converting it to bile acids.
Once in the liver, cholesterol can be secreted directly into bile via ABCG5/ABCG8 heterodimers or converted into bile acids by cytochrome P450 enzymes such as CYP7A1. Bile acids and free cholesterol are then excreted into the intestine and ultimately eliminated in feces. This final step represents the only route for net cholesterol removal from the body, and its efficiency determines the overall rate of reverse cholesterol transport.
Regulation by Active Cholesterol and miRNAs
In simple terms: The process is fine-tuned by the amount of active cholesterol in cells and by small regulatory RNAs.
Recent evidence suggests that reverse cholesterol transport is regulated by active cholesterol, a fraction of plasma membrane cholesterol that is not sequestered by sphingomyelin or other lipids. When active cholesterol levels rise, efflux transporters such as ABCA1 are stimulated to promote cholesterol removal. Additionally, microRNAs (miRNAs) such as miR-33, miR-758, and miR-106b have been shown to regulate the expression of genes involved in reverse cholesterol transport, including ABCA1 and ABCG1. Natural compounds and exercise can modulate these miRNAs and enhance reverse cholesterol transport.
Key Genes Involved in GO:0043691 reverse cholesterol transport
The following genes and proteins are central to reverse cholesterol transport, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ABCA1 | Mediates cholesterol efflux to lipid-poor apoA-I | Target for HDL-raising therapies; mutations cause Tangier disease |
| ABCG1 | Promotes cholesterol efflux to mature HDL | Modulates macrophage foam cell formation |
| APOA1 | Main apolipoprotein of HDL; acceptor for cholesterol efflux | Therapeutic target for increasing HDL |
| LCAT | Esterifies free cholesterol on HDL | Deficiency causes fish-eye disease and renal failure |
| CETP | Transfers cholesteryl esters from HDL to apoB lipoproteins | Inhibitor torcetrapib tested in clinical trials |
| SR-BI (SCARB1) | Mediates selective uptake of HDL cholesteryl esters in liver | Knockout models show impaired reverse cholesterol transport |
| CYP7A1 | Rate-limiting enzyme for bile acid synthesis | Regulates cholesterol catabolism |
| ABCG5 | Heterodimer with ABCG8; secretes cholesterol into bile | Mutations cause sitosterolemia |
| ABCG8 | Heterodimer with ABCG5; secretes cholesterol into bile | Mutations cause sitosterolemia |
| LDLR | Uptakes apoB lipoproteins carrying cholesteryl esters | Defects cause familial hypercholesterolemia |
| NR1H2 (LXRβ) | Nuclear receptor regulating ABCA1 and ABCG1 expression | Target for synthetic LXR agonists |
| NR1H3 (LXRα) | Nuclear receptor regulating cholesterol efflux and bile acid synthesis | Target for synthetic LXR agonists |
| PPARG | Regulates ABCA1 and ABCG1 expression in macrophages | Thiazolidinediones modulate reverse cholesterol transport |
| miR-33 | Inhibits ABCA1 and ABCG1 expression | Therapeutic target for increasing HDL |
| miR-758 | Inhibits ABCA1 expression | Regulates cholesterol efflux |
| miR-106b | Inhibits ABCA1 expression | Modulates reverse cholesterol transport |
| APOE | Lipoprotein involved in cholesterol transport and clearance | Isoforms affect cardiovascular risk |
| CETP | Cholesteryl ester transfer protein | Modulates HDL cholesterol levels |
How Is reverse cholesterol transport Regulated?
Reverse cholesterol transport is regulated at multiple levels, including transcriptional control by nuclear receptors such as LXRα and LXRβ, which induce ABCA1 and ABCG1 expression in response to cholesterol loading. Post-transcriptional regulation by microRNAs, including miR-33, miR-758, and miR-106b, modulates the expression of efflux transporters and other pathway components. Additionally, active cholesterol levels in the plasma membrane can directly stimulate efflux, providing a rapid regulatory mechanism. Exercise has been shown to enhance reverse cholesterol transport in animal studies, likely through effects on HDL metabolism and efflux capacity. Natural compounds, such as polyphenols, can also regulate reverse cholesterol transport-related miRNAs.
reverse cholesterol transport and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ABCA1 | Tangier disease; atherosclerosis | ABCA1 knockout mice; iPSC-derived macrophages |
| ABCG1 | Atherosclerosis; foam cell formation | ABCG1 knockout mice; macrophage-specific KO |
| SR-BI (SCARB1) | Cardiovascular disease; infertility | SR-BI knockout mice; liver-specific KO |
| CETP | Dyslipidemia; cardiovascular risk | CETP transgenic mice; human CETP expression models |
| LCAT | Fish-eye disease; renal failure | LCAT knockout mice; recombinant LCAT therapy |
Atherosclerosis and Cardiovascular Disease
Impaired reverse cholesterol transport is a major contributor to atherosclerosis, as reduced cholesterol efflux from macrophages leads to foam cell formation and plaque development. Clinical studies have shown that HDL cholesterol levels and efflux capacity are inversely correlated with cardiovascular risk. Genetic variants in ABCA1, ABCG1, and SR-BI have been associated with altered reverse cholesterol transport and atherosclerosis susceptibility. Therapeutic strategies aimed at enhancing reverse cholesterol transport, such as LXR agonists and CETP inhibitors, are under investigation.
Tangier Disease and HDL Deficiency
Mutations in ABCA1 cause Tangier disease, a rare disorder characterized by near-absence of HDL, cholesterol accumulation in macrophages, and increased cardiovascular risk. This condition underscores the critical role of ABCA1 in reverse cholesterol transport and HDL biogenesis. Studies of Tangier disease patients have provided key insights into the pathway's function and regulation.
Metabolic Disorders and Fatty Liver Disease
Dysregulation of reverse cholesterol transport has been implicated in non-alcoholic fatty liver disease (NAFLD) and insulin resistance. In NAFLD, hepatic cholesterol accumulation can impair SR-BI-mediated uptake and biliary excretion, exacerbating liver steatosis. Targeting reverse cholesterol transport components may offer therapeutic benefits for these metabolic conditions.
From reverse cholesterol transport-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of ABCA1 impair cholesterol efflux? | ABCA1 knockout cell line (e.g., HepG2, macrophages) |
| Does a point mutation in SR-BI affect HDL uptake? | SR-BI point-mutation knock-in mice or cells |
| Can overexpression of apoA-I enhance reverse cholesterol transport? | ApoA-I overexpression transgenic mice or lentiviral transduction |
| What is the role of miR-33 in regulating ABCA1? | miR-33 knockout or overexpression models |
| Does exercise modulate reverse cholesterol transport? | Animal exercise models with gene expression analysis |
| Can natural compounds regulate reverse cholesterol transport miRNAs? | Cell culture treated with polyphenols; miRNA profiling |
How to Study the reverse cholesterol transport Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Cholesterol efflux assay | Transfer of cholesterol from cells to acceptors | Assessing ABCA1/ABCG1 function |
| HDL isolation | HDL particle composition and size | Studying HDL maturation |
| qPCR | mRNA expression of target genes | Evaluating transcriptional regulation |
| RNA-seq | Global gene expression changes | Identifying novel regulators |
| In vivo tracer study | Cholesterol movement from macrophages to feces | Measuring whole-body reverse cholesterol transport |
| Western blot | Protein levels of transporters | Validating knockout or overexpression |
| miRNA profiling | Expression of regulatory miRNAs | Investigating post-transcriptional control |
| Bile acid quantification | Biliary cholesterol and bile acid output | Assessing hepatic catabolism |
Cholesterol Efflux Assays
Cholesterol efflux assays measure the ability of cells (e.g., macrophages) to transfer radiolabeled or fluorescent cholesterol to acceptors such as apoA-I or HDL. These assays are widely used to assess the functional capacity of reverse cholesterol transport in vitro and to evaluate the impact of genetic modifications.
HDL Isolation and Characterization
HDL can be isolated from plasma by ultracentrifugation or precipitation methods and characterized for size, composition, and cholesterol content. These techniques are essential for studying HDL maturation and function in reverse cholesterol transport.
Gene Expression Analysis (qPCR, RNA-seq)
Quantitative PCR and RNA sequencing are used to measure the expression of genes involved in reverse cholesterol transport, such as ABCA1, ABCG1, and SR-BI, under different experimental conditions. These methods help identify transcriptional regulation and miRNA-mediated effects.
In Vivo Tracer Studies
In vivo reverse cholesterol transport can be assessed by injecting radiolabeled cholesterol into macrophages and measuring its appearance in plasma, liver, bile, and feces. This approach provides a dynamic measure of the entire pathway and is considered the gold standard for evaluating reverse cholesterol transport in animal models.
How CRISPR Can Be Used to Study GO:0043691 reverse cholesterol transport
Knockout
CRISPR knockout of genes such as ABCA1, ABCG1, or SR-BI in cell lines or animal models is used to determine their causal role in reverse cholesterol transport. For example, ABCA1 knockout macrophages show severely impaired cholesterol efflux, confirming its essential function. Knockout models also help identify compensatory mechanisms and assess the impact on atherosclerosis development.
Point Mutation
CRISPR point mutation can introduce specific amino acid changes identified in human patients, such as those in ABCA1 causing Tangier disease, to study their functional consequences. This approach allows researchers to dissect the structure-function relationships of transporters and receptors involved in reverse cholesterol transport.
Knock-in
Knock-in of reporter tags (e.g., GFP) or human disease variants into endogenous loci enables real-time tracking of protein localization and function in reverse cholesterol transport. For example, tagging SR-BI with a fluorescent protein allows visualization of HDL uptake in hepatocytes.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of genes such as APOA1 or LCAT can enhance reverse cholesterol transport and is used to test therapeutic potential. Overexpression models help determine whether increasing a specific component can overcome pathway limitations and reduce atherosclerosis.
How EDITGENE Supports reverse cholesterol transport Research
Researchers studying reverse cholesterol transport-related genes often need to determine whether a candidate gene is causally involved in cholesterol efflux, HDL maturation, or hepatic uptake. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research, from gene knockout to precise point mutations and overexpression models.
Contact EDITGENE today to design your custom CRISPR model for reverse cholesterol transport research.
Frequently Asked Questions About reverse cholesterol transport
What is reverse cholesterol transport?
Reverse cholesterol transport is the biological process by which cholesterol from peripheral cells is transported to the liver for catabolism, as defined by GO:0043691.
What genes are involved in reverse cholesterol transport?
Key genes include ABCA1, ABCG1, APOA1, LCAT, CETP, SR-BI, CYP7A1, and ABCG5/ABCG8, among others.
How is reverse cholesterol transport regulated?
It is regulated by nuclear receptors such as LXR, microRNAs like miR-33, and active cholesterol levels.
What is the role of HDL in reverse cholesterol transport?
HDL particles accept cholesterol from peripheral cells and deliver it to the liver, serving as the main vehicle for reverse cholesterol transport.
Can exercise increase reverse cholesterol transport?
Animal studies suggest that exercise can enhance reverse cholesterol transport, likely by improving HDL function and cholesterol efflux.
What diseases are associated with impaired reverse cholesterol transport?
Impaired reverse cholesterol transport is linked to atherosclerosis, Tangier disease, and metabolic disorders such as fatty liver disease.
How can CRISPR be used to study reverse cholesterol transport?
CRISPR knockout, knock-in, point mutation, and overexpression models allow researchers to test the causal role of specific genes in the pathway.
What are the main steps of reverse cholesterol transport?
The main steps are cholesterol efflux from cells, HDL maturation and esterification, hepatic uptake, and biliary excretion or catabolism.
What is active cholesterol in reverse cholesterol transport?
Active cholesterol is a fraction of plasma membrane cholesterol that is not sequestered and can stimulate efflux transporters, regulating reverse cholesterol transport.
Which microRNAs regulate reverse cholesterol transport?
miR-33, miR-758, and miR-106b are examples of microRNAs that regulate genes involved in reverse cholesterol transport.
Conclusion
Reverse cholesterol transport (GO:0043691) is a vital biological process that removes excess cholesterol from peripheral tissues and delivers it to the liver for elimination. Its dysregulation is central to atherosclerosis and cardiovascular disease, making it a prime target for therapeutic intervention. Advances in CRISPR-based gene editing and high-throughput screening are accelerating the discovery of new regulators and drug targets within this pathway. Continued research into the molecular mechanisms, regulation, and genetic determinants of reverse cholesterol transport will be essential for developing effective strategies to combat cardiovascular and metabolic diseases.
References
- 1. Ouimet M et al.. 2019. HDL and Reverse Cholesterol Transport.. Circ Res 124(10):1505-1518 PMID: 31071007
- 2. Lian Z et al.. 2019. Reverse cholesterol transport-related miRNAs and their regulation by natural functional compounds.. Curr Protein Pept Sci 20(10):1004-1011 PMID: 31453783
- 3. Steck TL et al.. 2023. Is reverse cholesterol transport regulated by active cholesterol?. J Lipid Res 64(6):100385 PMID: 37169287
- 5. Ohashi R et al.. 2005. Reverse cholesterol transport and cholesterol efflux in atherosclerosis.. QJM 98(12):845-56 PMID: 16258026
- 6. Parini P. 2024. HDL, reverse cholesterol transport, and atherosclerosis: Unravelling the complexity or adding to the confusion?. Atherosclerosis 397:118562 PMID: 39137620
- 7. von Eckardstein A et al.. 2000. Acceleration of reverse cholesterol transport.. Curr Opin Cardiol 15(5):348-54 PMID: 11128188
- 8. Rahmati-Ahmadabad S et al.. 2019. Effects of exercise on reverse cholesterol transport: A systemized narrative review of animal studies.. Life Sci 224:139-148 PMID: 30922848
